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Lung cancer is currently the most common cause of can-
cer-related death in the world and approximately 85% of
all lung cancers are non-small cell lung cancer (NSCLC).
Previous studies have shown that patients with NSCLC
containing high densities of CD8+ memory T cells have a
survival advantage. Others have identified an association
between relatively high numbers of regulatory T cells and
poor prognosis. Our group is interested in better charac-
terizing the immune infiltrates and refining prognostic
biomarkers that identify patients at risk of recurrence.
Recent advances in multispectral imaging provide an
opportunity to evaluate up to 7 markers in a single 4
micron section of formalin-fixed paraffin-embedded
(FFPE) tissue. Using this technology, we reported that a
high ratio of CD8:FoxP3 at the tumor correlated with the
ability to isolate tumor-specific T cells from melanomas
(Feng et al., submitted). This determination could be
further improved by incorporating the ratio of CD8:PD-
L1 present in the tumor into the evaluation. Now we are
applying these same strategies to the study of NSCLC.
Initial analyses have been performed on more than 450
tumor cores from 77 patients with Stage 3A/3B/4
NSCLC and included the following markers: CD3, CD8,
FoxP3, CD163 and PD-L1. Additional markers are being
evaluated. Ultimately, we expect that this approach could
be used to stratify patients for clinical trials. We antici-
pate that some biomarkers will identify suppressive path-
ways and be associated with a short progression-free
survival. While we expect there will be heterogeneity in
escape mechanisms, identification of a specific mechan-
ism could be used to tailor therapy with an agent or
agents to overcome the specific immune suppressive
pathway operational in that specific tumor. Patients who
lack evidence for a specific suppressive pathway would be
randomized to treatment with combination immunother-
apy that includes a cancer vaccine.
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